# EDGAR Filing Document

**Accession Number:** 0001937993
**File Stem:** 0001213900-26-048169
**Filing Date:** 2026-4
**Character Count:** 2746
**Document Hash:** 26fca0664edb50628c35dcb2cad50d32
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-048169.hdr.sgml**: 20260528

**ACCESSION NUMBER**: 0001213900-26-048169

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260427

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cadrenal Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001937993
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 880860746
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 822 A1A NORTH
- **STREET 2:** SUITE 306
- **CITY:** PONTE VEDRA
- **STATE:** FL
- **ZIP:** 32082
- **BUSINESS PHONE:** 904-300-0701

**MAIL ADDRESS:**
- **STREET 1:** 822 A1A NORTH
- **STREET 2:** SUITE 306
- **CITY:** PONTE VEDRA
- **STATE:** FL
- **ZIP:** 32082

![](ea028794301_img1.jpg)

April 27, 2026

 ****

***<u>VIA EDGAR</u>***

United States Securities

and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Alan Campbell

---

| | |
|:---|:---|
| **Re:** | **Cadrenal Therapeutics, Inc.** |
|  | **Registration Statement on Form S-1** |
|  | **Filed April 21, 2026**<br> **File No: 333-295200** |

---

Dear Mr. Campbell:

Cadrenal Therapeutics, Inc. (the "**Registrant**") hereby requests that the effective date of the above-referenced Registration Statement on Form S-3 (File No. 333-295200), be accelerated by the U.S. Securities and Exchange Commission (the "**Commission**") to become effective on **Wednesday, April 29, 2026**, at 5**:00 p.m**., Eastern Time, or as soon as reasonably practicable thereafter.

The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.

The Registrant hereby authorizes Leslie Marlow and/or Jamie Plisner of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (212) 885-5358 or Ms. Plisner at (212) 885-5298 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.

Thank you.

---

| | | |
|:---|:---|:---|
| Very truly yours, | Very truly yours, | Very truly yours, |
| CADRENAL THERAPEUTICS, INC. | CADRENAL THERAPEUTICS, INC. | CADRENAL THERAPEUTICS, INC. |
| By: | /s/ Quang Pham | /s/ Quang Pham |
|  | Name: | Quang Pham |
|  | Title: | Chief Executive Officer |

---

cc: Leslie Marlow, Blank Rome LLP <br> Jamie Plisner, Blank Rome LLP